Legal14 Nov 2025, 03:39 pm
Glenmark Pharmaceuticals Settles Antitrust and Consumer Protection Lawsuits for $18 Million
AI Summary
Glenmark Pharmaceuticals Ltd. has announced that it has settled antitrust and consumer protection lawsuits related to generic Zetia® and Vytorin® for a total of $18 million. The lawsuits, which were originally filed in the Eastern District of Virginia, U.S., were consolidated and included claims that Glenmark entered an anticompetitive agreement to settle patent infringement litigation involving a patent related to ezetimibe, the active ingredient in Zetia. Glenmark has denied all allegations and the settlement is not on the basis of any conceded liability or illegality. The settlement resolves all generic Zetia® and Vytorin® antitrust and consumer protection litigations.
Key Highlights
- Glenmark Pharmaceuticals settles antitrust and consumer protection lawsuits for $18 million.
- The lawsuits were related to generic Zetia® and Vytorin®, drugs for the treatment of cholesterol.
- The settlement resolves all generic Zetia® and Vytorin® antitrust and consumer protection litigations.
- Glenmark has denied all allegations and the settlement is not on the basis of any conceded liability or illegality.
- The lawsuits were originally filed in the Eastern District of Virginia, U.S., and were consolidated in 2023.